These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 10636116)

  • 1. The question of familial meningiomas and schwannomas: NF2B or not to be?
    King A; Gutmann DH
    Neurology; 2000 Jan; 54(1):4-5. PubMed ID: 10636116
    [No Abstract]   [Full Text] [Related]  

  • 2. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas.
    Antinheimo J; Sankila R; Carpén O; Pukkala E; Sainio M; Jääskeläinen J
    Neurology; 2000 Jan; 54(1):71-6. PubMed ID: 10636128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined molecular genetic studies of chromosome 22q and the neurofibromatosis type 2 gene in central nervous system tumors.
    Ng HK; Lau KM; Tse JY; Lo KW; Wong JH; Poon WS; Huang DP
    Neurosurgery; 1995 Oct; 37(4):764-73. PubMed ID: 8559307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline deletion in a neurofibromatosis type 2 kindred inactivates the NF2 gene and a candidate meningioma locus.
    Sanson M; Marineau C; Desmaze C; Lutchman M; Ruttledge M; Baron C; Narod S; Delattre O; Lenoir G; Thomas G
    Hum Mol Genet; 1993 Aug; 2(8):1215-20. PubMed ID: 8401504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clonal analysis of human meningiomas and schwannomas.
    Jacoby LB; Pulaski K; Rouleau GA; Martuza RL
    Cancer Res; 1990 Nov; 50(21):6783-6. PubMed ID: 2208143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meningiomas and schwannomas: molecular subgroup classification found by expression arrays.
    Martinez-Glez V; Franco-Hernandez C; Alvarez L; De Campos JM; Isla A; Vaquero J; Lassaletta L; Casartelli C; Rey JA
    Int J Oncol; 2009 Feb; 34(2):493-504. PubMed ID: 19148485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Genetic Predisposition With Solitary Schwannoma or Meningioma in Children and Young Adults.
    Pathmanaban ON; Sadler KV; Kamaly-Asl ID; King AT; Rutherford SA; Hammerbeck-Ward C; McCabe MG; Kilday JP; Beetz C; Poplawski NK; Evans DG; Smith MJ
    JAMA Neurol; 2017 Sep; 74(9):1123-1129. PubMed ID: 28759666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The neurofibromatosis type 2 gene is inactivated in schwannomas.
    Twist EC; Ruttledge MH; Rousseau M; Sanson M; Papi L; Merel P; Delattre O; Thomas G; Rouleau GA
    Hum Mol Genet; 1994 Jan; 3(1):147-51. PubMed ID: 8162016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comment on the article "Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri" by van den Munckhof et al.
    Prescott TE; Smith MJ; Evans DG
    Neurogenetics; 2012 Feb; 13(1):103-4. PubMed ID: 22203059
    [No Abstract]   [Full Text] [Related]  

  • 10. [Sporadic familial meningiomas].
    Medrano-Martínez V; Moltó-Jordà JM; Sánchez-Pérez RM; Castaño-Pérez MD; Arenas J; Beltrán-Blasco I
    Rev Neurol; 2000 Sep 1-15; 31(5):433-5. PubMed ID: 11027095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial meningioma is not allelic to neurofibromatosis 2.
    Pulst SM; Rouleau GA; Marineau C; Fain P; Sieb JP
    Neurology; 1993 Oct; 43(10):2096-8. PubMed ID: 8413972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset.
    Smith MJ; Higgs JE; Bowers NL; Halliday D; Paterson J; Gillespie J; Huson SM; Freeman SR; Lloyd S; Rutherford SA; King AT; Wallace AJ; Ramsden RT; Evans DG
    J Med Genet; 2011 Apr; 48(4):261-5. PubMed ID: 21278391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between natural history and multi-omics profiling of meningiomas in NF2-related schwannomatosis suggests role of methylation group and immune microenvironment in tumor growth rate.
    Teranishi Y; Yurchenko A; Tran S; Sievers P; Rajabi F; Ruchith S; Abi-Jaoude S; Blouin A; Bielle F; Cazals-Hatem D; Sahm F; Nikolaev S; Kalamarides M; Peyre M
    Acta Neuropathol; 2024 Aug; 148(1):30. PubMed ID: 39192083
    [No Abstract]   [Full Text] [Related]  

  • 14. Hereditary tumors of the nervous system.
    Ponz de Leon M
    Recent Results Cancer Res; 1994; 136():84-93. PubMed ID: 7863109
    [No Abstract]   [Full Text] [Related]  

  • 15. Cases of Mixed Schwannoma-Meningioma With and Without Neurofibromatosis 2 with Emphasis on Tumorigenesis.
    Rajeswarie RT; Mallik D; Rudrappa S; Gopal S
    Int J Surg Pathol; 2024 May; 32(3):511-514. PubMed ID: 37487199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytogenetic analysis of meningiomas.
    Cho JH; Gong GY; Yu ES; Whang CJ; Jee KJ; Lee I
    J Korean Med Sci; 1992 Jun; 7(2):162-6. PubMed ID: 1524729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple Meningiomas as a Criterion for the Diagnosis of Neurofibromatosis Type 2 and Other Tumor Predisposition Syndromes.
    Hannan CJ; Hammerbeck-Ward C; Pathmanaban ON; Smith MJ; Rutherford SA; Lloyd SK; Mackenzie Freeman SR; Wallace AJ; King AT; Richard Evans DG
    Neurosurgery; 2022 Jun; 90(6):793-799. PubMed ID: 35343466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value and management of spinal tumors in neurofibromatosis type 2 patients.
    Aboukais R; Baroncini M; Zairi F; Bonne NX; Schapira S; Vincent C; Lejeune JP
    Acta Neurochir (Wien); 2013 May; 155(5):771-7. PubMed ID: 23381342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.
    ; Allaway R; Angus SP; Beauchamp RL; Blakeley JO; Bott M; Burns SS; Carlstedt A; Chang LS; Chen X; Clapp DW; Desouza PA; Erdin S; Fernandez-Valle C; Guinney J; Gusella JF; Haggarty SJ; Johnson GL; La Rosa S; Morrison H; Petrilli AM; Plotkin SR; Pratap A; Ramesh V; Sciaky N; Stemmer-Rachamimov A; Stuhlmiller TJ; Talkowski ME; Welling DB; Yates CW; Zawistowski JS; Zhao WN
    PLoS One; 2018; 13(6):e0197350. PubMed ID: 29897904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focal Adhesion Kinase as a Therapeutic Target for Meningiomas With Somatic Neurofibromatosis Type 2 Mutations.
    Mason WP
    J Clin Oncol; 2023 Jan; 41(3):675-677. PubMed ID: 36288506
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.